Updated

Novo Nordisk's push into pediatric obesity treatment is facing a more significant test, according to new analysis, as the company seeks to expand its weight-loss drug franchise into younger patient populations. The opportunity represents a potential new growth avenue but comes with added regulatory and clinical scrutiny. The report examined the commercial and medical challenges facing Novo Nordisk as it works to broaden the addressable market for its obesity treatments beyond adults.